The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis

K. E. Hansen, J. Cush, A. Singhal, D. A. Cooley, S. Cohen, S. R. Patel, M. Genovese, S. Sundaramurthy, M. Schiff

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective. To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis. Methods. In an open, multicenter, retrospective study, data were collected on the safety and efficacy of LEF and INF. Results. Eighty-eight patients received the combination of LEF and INF for an average of 6.6 months and a total exposure of 581 patient-months. The mean duration of LEF was 17 ± 9 months (range 3-32 months; median 18.5 months) with an average of 4.8 INF infusions per patient. In all but 3 subjects, LEF was used initially and INF was added later. Infusion reactions occurred in 3 patients (0.7% of all infusions). A total of 34% of subjects experienced adverse events and in 6 (6. 8% of the group) these were deemed serious. Ten infections occurred when patients were taking the combination; 9 patients recovered fully and 1 died of bacterial pneumonia. A lifetime smoker developed lung cancer and another patient was found to have colon cancer. Conclusions. The adverse events noted within the combination therapy group were in keeping with the known risks of each drug when used individually. Limited data were available on efficacy, but a general improvement in disease control was noted with the combination of drugs, which for most patients involved the addition of INF to previous use of LEF.

Original languageEnglish (US)
Pages (from-to)228-232
Number of pages5
JournalArthritis Care and Research
Volume51
Issue number2
StatePublished - Apr 15 2004
Externally publishedYes

Fingerprint

leflunomide
Rheumatoid Arthritis
Safety
Bacterial Pneumonia
Infliximab
Drug Combinations
Group Psychotherapy
Colonic Neoplasms
Multicenter Studies

Keywords

  • Combination therapy
  • Infliximab
  • Leflunomide
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Hansen, K. E., Cush, J., Singhal, A., Cooley, D. A., Cohen, S., Patel, S. R., ... Schiff, M. (2004). The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis. Arthritis Care and Research, 51(2), 228-232.

The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis. / Hansen, K. E.; Cush, J.; Singhal, A.; Cooley, D. A.; Cohen, S.; Patel, S. R.; Genovese, M.; Sundaramurthy, S.; Schiff, M.

In: Arthritis Care and Research, Vol. 51, No. 2, 15.04.2004, p. 228-232.

Research output: Contribution to journalArticle

Hansen, KE, Cush, J, Singhal, A, Cooley, DA, Cohen, S, Patel, SR, Genovese, M, Sundaramurthy, S & Schiff, M 2004, 'The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis', Arthritis Care and Research, vol. 51, no. 2, pp. 228-232.
Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR et al. The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis. Arthritis Care and Research. 2004 Apr 15;51(2):228-232.
Hansen, K. E. ; Cush, J. ; Singhal, A. ; Cooley, D. A. ; Cohen, S. ; Patel, S. R. ; Genovese, M. ; Sundaramurthy, S. ; Schiff, M. / The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis. In: Arthritis Care and Research. 2004 ; Vol. 51, No. 2. pp. 228-232.
@article{89c04ab33dd841a79dbd13df92c99cce,
title = "The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis",
abstract = "Objective. To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis. Methods. In an open, multicenter, retrospective study, data were collected on the safety and efficacy of LEF and INF. Results. Eighty-eight patients received the combination of LEF and INF for an average of 6.6 months and a total exposure of 581 patient-months. The mean duration of LEF was 17 ± 9 months (range 3-32 months; median 18.5 months) with an average of 4.8 INF infusions per patient. In all but 3 subjects, LEF was used initially and INF was added later. Infusion reactions occurred in 3 patients (0.7{\%} of all infusions). A total of 34{\%} of subjects experienced adverse events and in 6 (6. 8{\%} of the group) these were deemed serious. Ten infections occurred when patients were taking the combination; 9 patients recovered fully and 1 died of bacterial pneumonia. A lifetime smoker developed lung cancer and another patient was found to have colon cancer. Conclusions. The adverse events noted within the combination therapy group were in keeping with the known risks of each drug when used individually. Limited data were available on efficacy, but a general improvement in disease control was noted with the combination of drugs, which for most patients involved the addition of INF to previous use of LEF.",
keywords = "Combination therapy, Infliximab, Leflunomide, Rheumatoid arthritis",
author = "Hansen, {K. E.} and J. Cush and A. Singhal and Cooley, {D. A.} and S. Cohen and Patel, {S. R.} and M. Genovese and S. Sundaramurthy and M. Schiff",
year = "2004",
month = "4",
day = "15",
language = "English (US)",
volume = "51",
pages = "228--232",
journal = "Arthritis Care and Research",
issn = "2151-464X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - The Safety and Efficacy of Leflunomide in Combination with Infliximab in Rheumatoid Arthritis

AU - Hansen, K. E.

AU - Cush, J.

AU - Singhal, A.

AU - Cooley, D. A.

AU - Cohen, S.

AU - Patel, S. R.

AU - Genovese, M.

AU - Sundaramurthy, S.

AU - Schiff, M.

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Objective. To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis. Methods. In an open, multicenter, retrospective study, data were collected on the safety and efficacy of LEF and INF. Results. Eighty-eight patients received the combination of LEF and INF for an average of 6.6 months and a total exposure of 581 patient-months. The mean duration of LEF was 17 ± 9 months (range 3-32 months; median 18.5 months) with an average of 4.8 INF infusions per patient. In all but 3 subjects, LEF was used initially and INF was added later. Infusion reactions occurred in 3 patients (0.7% of all infusions). A total of 34% of subjects experienced adverse events and in 6 (6. 8% of the group) these were deemed serious. Ten infections occurred when patients were taking the combination; 9 patients recovered fully and 1 died of bacterial pneumonia. A lifetime smoker developed lung cancer and another patient was found to have colon cancer. Conclusions. The adverse events noted within the combination therapy group were in keeping with the known risks of each drug when used individually. Limited data were available on efficacy, but a general improvement in disease control was noted with the combination of drugs, which for most patients involved the addition of INF to previous use of LEF.

AB - Objective. To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis. Methods. In an open, multicenter, retrospective study, data were collected on the safety and efficacy of LEF and INF. Results. Eighty-eight patients received the combination of LEF and INF for an average of 6.6 months and a total exposure of 581 patient-months. The mean duration of LEF was 17 ± 9 months (range 3-32 months; median 18.5 months) with an average of 4.8 INF infusions per patient. In all but 3 subjects, LEF was used initially and INF was added later. Infusion reactions occurred in 3 patients (0.7% of all infusions). A total of 34% of subjects experienced adverse events and in 6 (6. 8% of the group) these were deemed serious. Ten infections occurred when patients were taking the combination; 9 patients recovered fully and 1 died of bacterial pneumonia. A lifetime smoker developed lung cancer and another patient was found to have colon cancer. Conclusions. The adverse events noted within the combination therapy group were in keeping with the known risks of each drug when used individually. Limited data were available on efficacy, but a general improvement in disease control was noted with the combination of drugs, which for most patients involved the addition of INF to previous use of LEF.

KW - Combination therapy

KW - Infliximab

KW - Leflunomide

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=1842629562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842629562&partnerID=8YFLogxK

M3 - Article

C2 - 15077264

AN - SCOPUS:1842629562

VL - 51

SP - 228

EP - 232

JO - Arthritis Care and Research

JF - Arthritis Care and Research

SN - 2151-464X

IS - 2

ER -